Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Continuing Enasidenib Treatment for Patients with Mutant- IDH2 (m IDH2 ) Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with Stable Disease May Result in Improved Survival and Responses over Time

Eytan M. Stein, MD, Richard M. Stone, MD, Daniel A. Pollyea, MD, Gail J. Roboz, MD, Jessica K. Altman, MD, Courtney D. DiNardo, MDMSc, Stephane de Botton, MD PhD, Nora Tu, PhD, Arlene S. Swern, PhD, Alessandra Tosolini, BS, Ira Gupta, MD, Samuel V. Agresta, MD, Amir T. Fathi, MD MD BS

Blood (2017) 130 (Supplement 1): 1299.

https://doi.org/10.1182/blood.V130.Suppl_1.1299.1299

Published: 2017

Journal Articles

Undertreatment of Patients (Pts) with Myelodysplastic Syndromes (MDS): Analysis of a Large Electronic Medical Records (EMR) Database Cohort of US Pts with MDS

David P. Steensma, MD, Bart L Scott, MD, Xiaomei Ma, PhD, Albert Fliss, PhD, Pavel Kiselev, PhD, Arlene S. Swern, PhD, Mary M. Sugrue, MD PhD

Blood (2016) 128 (22): 4768.

https://doi.org/10.1182/blood.V128.22.4768.4768

Published: 2016

Journal Articles

Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the Connect ® CLL Registry

Jeff Sharman, MD, Matthew Davids, MD, Charles Michael Farber, MD PhD, David L. Grinblatt, MD, Neil E. Kay, MD, Nicole Lamanna, MD, Anthony R. Mato, MD, Chadi Nabhan, MD MBA, FACP, Kristen Sullivan, MBA, CCRA, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Christopher R. Flowers, MD

Blood (2016) 128 (22): 5941.

https://doi.org/10.1182/blood.V128.22.5941.5941

Published: 2016

Journal Articles

Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect ® MM Disease Registry

Rafat Abonour, MD, Brian G.M. Durie, MD, Sundar Jagannath, MD, Jatin J. Shah, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Cristina J. Gasparetto, MD, Kathleen Toomey, MD, James W. Hardin, PhD, Amani Kitali, MPH, PMP, Craig Gibson, PhD, Shankar Srinivasan, PhD, Arlene S. Swern, PhD, Robert M. Rifkin, MD

Blood (2016) 128 (22): 537.

https://doi.org/10.1182/blood.V128.22.537.537

Published: 2016

Journal Articles

Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect ® CLL Registry

Inhye E Ahn, MD, Charles Michael Farber, MD PhD, Matthew Davids, MD, David L. Grinblatt, MD, Nicole Lamanna, MD, Anthony R. Mato, MDMSCE, Chadi Nabhan, MD MBA, FACP, Pavel Kiselev, PhD, Arlene S. Swern, PhD, E. Dawn Flick, RPh, MPH, ScD, Shriya Bhushan, PharmD, Kristen Sullivan, MBA, CCRA, Jeff Sharman, MD, Christopher R. Flowers, MD

Blood (2016) 128 (22): 3581.

https://doi.org/10.1182/blood.V128.22.3581.3581

Published: 2016

Journal Articles

Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT ® Myelodysplastic Syndromes (MDS) and AML Disease Registry

Blood (2016) 128 (22): 3548.

https://doi.org/10.1182/blood.V128.22.3548.3548

Published: 2016

Journal Articles

Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL® Registry

Charles M. Farber, MD, Anthony Mato, MD, Chadi Nabhan, MD, Thomas J. Kipps, MD, PhD, Christopher Flowers, MD, Neil E. Kay, MD, Nicole Lamanna, MD, David L. Grinblatt, MD, Mark Kozloff, MD, Mark Weiss, MD, Kristen Sullivan, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Jeff P. Sharman, MD

Blood (2015) 126 (23): 5270.

https://doi.org/10.1182/blood.V126.23.5270.5270

Published: 2015

Journal Articles

Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry

Anthony Mato, MD, Chadi Nabhan, MD, Christopher Flowers, MD, Neil E. Kay, MD, Thomas J. Kipps, MD, PhD, David L. Grinblatt, MD, Nicole Lamanna, MD, Mark Kozloff, MD, Kristen Sullivan, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Jeff P. Sharman, MD

Blood (2015) 126 (23): 4483.

https://doi.org/10.1182/blood.V126.23.4483.4483

Published: 2015

Journal Articles

Use of an Electronic Medical Record (EMR) Database to Identify a Real-World Cohort of US Patients (Pts) with Myelodysplastic Syndromes (MDS)

Xiaomei Ma, PhD, Arlene S. Swern, PhD, Pavel Kiselev, PhD, Albert Fliss, PhD, Jane J. Lu, MS, Bart L. Scott, MD, David P. Steensma, MD, Mary M. Sugrue, MD PhD

Blood (2015) 126 (23): 3319.

https://doi.org/10.1182/blood.V126.23.3319.3319

Published: 2015

Journal Articles

Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL® Cohort Study

Christopher Flowers, MD, Chadi Nabhan, MD, Neil E. Kay, MD, Anthony Mato, MD, Nicole Lamanna, MD, David L. Grinblatt, MD, Thomas J. Kipps, MD, PhD, Mark Kozloff, MD, Kristen Sullivan, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Jeff P. Sharman, MD

Blood (2015) 126 (23): 3284.

https://doi.org/10.1182/blood.V126.23.3284.3284

Published: 2015

Journal Articles

Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide

Aaron T. Gerds, MD MS, Alan F. List, MD, Aristoteles Giagounidis, MD PhD, Eva Hellström-Lindberg, MD PhD, Jack Shiansong Li, PhD, Arlene S. Swern, PhD, Mary M. Sugrue, MD PhD, Pierre Fenaux, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2015) 126 (23): 2867.

https://doi.org/10.1182/blood.V126.23.2867.2867

Published: 2015

Journal Articles

Effect of Lenalidomide (LEN) Exposure on AML-Free Survival and Overall Survival in LEN-Treated Patients (Pts) with IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS) with Del(5q)

Mikkael A. Sekeres, MD MS, Arlene S. Swern, PhD, Alan F. List, MD, Pierre Fenaux, MD PhD, Mary M. Sugrue, MD PhD

Blood (2015) 126 (23): 2870.

https://doi.org/10.1182/blood.V126.23.2870.2870

Published: 2015

Journal Articles

Patterns of Care of Aged Chronic Lymphocytic Leukemia Patients in the United States: Systematic Analysis of 457 Patients in the Connect CLL Registry

Chadi Nabhan, MD FACP, Natalie Galanina, MD, Neil E. Kay, MD, Anthony R. Mato, MD, David L. Grinblatt, MD, Thomas J. Kipps, MD, Nicole Lamanna, MD, Mark Weiss, MD, Ian Flinn, Arlene S. Swern, PhD, Thomas Street, Sullivan Kristen, MBA, Christopher R. Flowers, MD

Blood (2014) 124 (21): 4672.

https://doi.org/10.1182/blood.V124.21.4672.4672

Published: 2014

Journal Articles

p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study

Leonie Saft, MD PhD, Jack Shiansong Li, PhD, Peter L. Greenberg, MD PhD, Mikkael A. Sekeres, MD MS, Guillermo F. Sanz, MD PhD, François Dreyfus, MD, Pierre Fenaux, MD PhD, Arlene S. Swern, PhD, Mary M. Sugrue, MD PhD, Eva Hellstrom-Lindberg, MD PhD

Blood (2014) 124 (21): 414.

https://doi.org/10.1182/blood.V124.21.414.414

Published: 2014

Journal Articles

Demographics By Age Group (AG) and Line of Therapy (LOT) in Chronic Lymphocytic Leukemia (CLL) Patients (Pts) Treated in US Practices from the Connect ® CLL Registry

Jeff P. Sharman, MD, Anthony Mato, Neil E. Kay, MD, Thomas J. Kipps, MD, Nicole Lamanna, Mark Weiss, MD, Chadi Nabhan, Ian Flinn, David L. Grinblatt, Mark F. Kozloff, Charles M. Farber, Kirsten Sullivan, Thomas Street, Arlene S. Swern, PhD, Christopher R. Flowers, MD

Blood (2014) 124 (21): 3338.

https://doi.org/10.1182/blood.V124.21.3338.3338

Published: 2014

Journal Articles

Real-World Analysis Of Celgene Global Drug Safety (GDS) Database: Early Permanent Discontinuation (D/C) Of Lenalidomide (LEN) In Patients (Pts) With Myelodysplastic Syndromes (MDS) Due To Nonserious (NS) Rash

Lilia Weiss, MD, Dianna Gary, BSN, RN, Arlene S. Swern, PhD, John Freeman, MD, Mary M. Sugrue, MD, PhD

Blood (2013) 122 (21): 2975.

https://doi.org/10.1182/blood.V122.21.2975.2975

Published: 2013

Journal Articles

Association Of Cytogenetic Response (CyR) With RBC Transfusion-Independence (RBC-TI) and AML-Free Survival In Lenalidomide (LEN)-Treated Patients (Pts) With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) With Del(5q)

Mikkael A. Sekeres, MD, MS, Arlene S. Swern, PhD, Aristoteles Giagounidis, MD, PhD, Alan List, MD, Brigitte Schlegelberger, MD, PhD, Pierre Fenaux, MD, PhD, Jack Shiansong Li, Mary M. Sugrue, MD, PhD

Blood (2013) 122 (21): 390.

https://doi.org/10.1182/blood.V122.21.390.390

Published: 2013

Journal Articles

Variation in Health-Related Quality of Life by Line of Therapy of Patients with Chronic Lymphocytic Leukemia

Neil E. Kay, MD, Christopher R. Flowers, MD, Mark Weiss, MD, Nicole Lamanna, MD, Ian W. Flinn, MD, PhD, David Grinblatt, MD, Thomas J. Kipps, MD, PhD, Mark Kozloff, Susan Lerner, MS, Jeff Sharman, MD, Ren Yu, MA, Zeba M. Khan, PhD, Thomas K. Street, RPh, Arlene S. Swern, PhD, Kristen A. Sullivan, MBA, Chris L Pashos, PhD

Blood (2012) 120 (21): 3926.

https://doi.org/10.1182/blood.V120.21.3926.3926

Published: 2012

Journal Articles

Variation in Health-Related Quality of Life by ECOG Performance Status and Fatigue Among Patients with Chronic Lymphocytic Leukemia

Chris L. Pashos, PhD, Christopher R Flowers, MD, Mark Weiss, MD, Nicole Lamanna, MD, Charles M Farber, MD, PhD, Thomas J. Kipps, M.D., Ph.D, Susan Lerner, MS, BA, Neil Kay, MD, Jeff Porte Sharman, MD, David L. Grinblatt, MD, Ian W. Flinn, MD, PhD, Mark Kozloff, MD, Arlene S Swern, PhD, Zeba M. Kahn, Ph.D, Thomas K. Street, RPh, Gale Harding, MA, Kristen A Sullivan, MBA, Michael J Keating, MD

Blood (2011) 118 (21): 4591.

https://doi.org/10.1182/blood.V118.21.4591.4591

Published: 2011

Journal Articles

Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia

Chris L. Pashos, PhD, Christopher R Flowers, MD, Mark Weiss, MD, Nicole Lamanna, MD, Charles M Farber, MD, PhD, Thomas J. Kipps, M.D., Ph.D, Susan Lerner, MS, BA, Neil Kay, MD, Jeff Porte Sharman, MD, David L. Grinblatt, MD, Ian W. Flinn, MD, PhD, Mark Kozloff, MD, Arlene S Swern, PhD, Zeba M. Kahn, Ph.D, Thomas K. Street, RPh, Kristen A Sullivan, MBA, Gale Harding, MA, Michael J Keating, MD

Blood (2011) 118 (21): 2085.

https://doi.org/10.1182/blood.V118.21.2085.2085

Published: 2011

NARROW

Continuing Enasidenib Treatment for Patients with Mutant- IDH2 (m IDH2 ) Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with Stable Disease May Result in Improved Survival and Responses over Time

Undertreatment of Patients (Pts) with Myelodysplastic Syndromes (MDS): Analysis of a Large Electronic Medical Records (EMR) Database Cohort of US Pts with MDS

Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the Connect ® CLL Registry

Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect ® MM Disease Registry

Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect ® CLL Registry

Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT ® Myelodysplastic Syndromes (MDS) and AML Disease Registry

Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL® Registry

Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry

Use of an Electronic Medical Record (EMR) Database to Identify a Real-World Cohort of US Patients (Pts) with Myelodysplastic Syndromes (MDS)

Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL® Cohort Study

Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide

Effect of Lenalidomide (LEN) Exposure on AML-Free Survival and Overall Survival in LEN-Treated Patients (Pts) with IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS) with Del(5q)

Patterns of Care of Aged Chronic Lymphocytic Leukemia Patients in the United States: Systematic Analysis of 457 Patients in the Connect CLL Registry

p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study

Demographics By Age Group (AG) and Line of Therapy (LOT) in Chronic Lymphocytic Leukemia (CLL) Patients (Pts) Treated in US Practices from the Connect ® CLL Registry

Real-World Analysis Of Celgene Global Drug Safety (GDS) Database: Early Permanent Discontinuation (D/C) Of Lenalidomide (LEN) In Patients (Pts) With Myelodysplastic Syndromes (MDS) Due To Nonserious (NS) Rash

Association Of Cytogenetic Response (CyR) With RBC Transfusion-Independence (RBC-TI) and AML-Free Survival In Lenalidomide (LEN)-Treated Patients (Pts) With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) With Del(5q)

Variation in Health-Related Quality of Life by Line of Therapy of Patients with Chronic Lymphocytic Leukemia

Variation in Health-Related Quality of Life by ECOG Performance Status and Fatigue Among Patients with Chronic Lymphocytic Leukemia

Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only